首页> 美国卫生研究院文献>AAPS PharmSciTech >In Vitro-Controlled Release Delivery System for Hydrogen Sulfide Donor
【2h】

In Vitro-Controlled Release Delivery System for Hydrogen Sulfide Donor

机译:硫化氢供体的体外控制释放释放系统

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hydrogen sulfide (H2S) is having many potential pharmacological and physiological actions which reported that therapeutically useful concentration is low (100–160 μM) and a higher concentration could be toxic. Most of its donors produce it on coming into contact with water. All of these problems could be solved by a controlled-release delivery system which does not utilize water in any of its development steps. Therefore, 12 sustained release formulations were prepared by dissolving sodium hydrogen sulfide (NaHS)—a model H2S donor—in polymer solutions, prepared by dissolving polymers (consisted of either polylactide (PLA) or polylactide co-glycolide (PLGA), containing free carboxylic acid or capped allyl ester end group) in a mixture of benzyl benzoate (BB) and benzyl alcohol (BA). The formulation was injected in simulated tear fluid (STF) from which samples were withdrawn at specified times and assayed for NaHS content. We found decrease in burst and overall release with increase in polymer concentration from 10 to 20% w/v. The formulations containing free end group showed significant (p < 0.05) reduction of burst release (11% vs 21%). However, the overall release or the average amount released per hour was found to be significantly (p < 0.05) increased for formulations containing polymers with free end group than those with capped end group. A sustained level of H2S was found to be maintained for 72 h which should be further increased to a month to make it a viable H2S donor delivery system in addition to investigating toxicity profile specifically for the purpose of subconjunctival ocular delivery.
机译:硫化氢(H2S)具有许多潜在的药理和生理作用,据报告治疗有效浓度较低(100-160μM),较高的浓度可能有毒。它的大多数捐助者是在与水接触时生产的。所有这些问题都可以通过控释输送系统解决,该系统在其任何开发步骤中均不使用水。因此,通过将硫化氢钠(NaHS)(一种H2S供体模型)溶解在聚合物溶液中来制备12种缓释制剂,该溶液是通过溶解含有游离羧酸的聚合物(由聚丙交酯(PLA)或聚丙交酯乙交酯(PLGA)组成)制备的苯甲酸苄酯(BB)和苯甲醇(BA)的混合物中的酸或带帽烯丙基酯端基)。将制剂注射到模拟泪液(STF)中,在指定的时间从中取出样品并分析NaHS含量。我们发现,随着聚合物浓度从10%至20%w / v的增加,破裂和总体释放的降低。含有游离端基的制剂显示出突释的显着降低(p <0.05)(11%对21%)。然而,发现含有游离端基的聚合物的配方的总释放量或每小时的平均释放量显着增加(p <0.05),而没有端基封端的聚合物。已发现将H2S的持续水平维持72小时,并应进一步将其延长至一个月以使其成为可行的H2S供体输送系统,此外还专门研究结膜下眼部输送的毒性特征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号